Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177lu-DOTATATE and 90Y-DOTATOC

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 6, 2009, Pages 659-665

  Sierra, Maribel L ^a   Agazzi, Alberto ^a   Bodei, Lisa ^a   Pacifici, Monica ^a   Aricò, Demetrio ^a   De Cicco, Concetta ^a   Quarna, Jessica ^a   Sansovini, Maddalena ^b   De Simone, Michele ^c   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

Radionuclide therapy; Radiopharmaceuticals; Targeted therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE Y 90; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; BLOOD TOXICITY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; B-LYMPHOCYTES; COLONIC NEOPLASMS; DUODENAL NEOPLASMS; FEMALE; HUMANS; ILEAL NEOPLASMS; LUNG NEOPLASMS; LUTETIUM; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; YTTRIUM RADIOISOTOPES;

EID: 73649099888     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0641     Document Type: Article

References (31)

1. Patel YC, Greenwood MT, Panetta R, et al. The somatostatin receptor family [review]. Life Sci 1995;57:1249.
2. Bruns C, Weckbecker G, Raulf F, et al. Characterization of somatostatin receptor subtypes [review]. Ciba Found Symp 1995;190:89.
3. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90YDOTATOC. J Nucl Med 2002;43:610.
4. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs [review]. J Nucl Med 2005;46(Suppl 1):62S.
5. Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1038.
6. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog, [177Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124.
7. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptortargeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002;32:133.
8. Cremonesi M, Ferrari M, Bodei L, et al. Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 2006; 47:1467.
9. Brans B, Bodei L, Giammarile F, et al. Clinical radionuclide theraphy dosimetry: The quest for the "Holy Grial." Eur J Nucl Med Mol Imaging 2007;34:772.
10. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754.
11. National Council on Radiation Protection and Measurements. Misadministration of radioactive material in medicine- scientific background. Bethesda, MD: NCRP, 1991;27.
12. Bernard BF, Krenning EP, Breeman WA, et al. d-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929.
13. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]- octreotide: The Rotterdam experience. Semin Nucl Med 2002;32:110.
14. Bodei L. Ferone D, Grana CM, et al. Peptide receptor therapies in neuroendocrine tumours. J Endocrinol Invest 2009;32:360.
15. Bhathena SJ, Louie J, Schechter GP, et al. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon. Diabetes 1981;30:127.
16. Ferone D, van Hagen PM, van Koetsveld PM, et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999;140: 373.
17. Van Hagen PM, Krenning EP, Kwekkeboom DJ, et al. Somatostatin and the immune and haematopoetic system: A review. Eur J Clin Invest 1994;4:91.
18. Paganelli G, Zoboli S, Cremonesi M, et al. Receptormediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28:426.
19. Chinol M, Bodei L, Cremonesi M, et al. Receptor-mediated radiotherapy with Y-DOTA-dPhe-Tyr-octreotide: The experience of the European Institute of Oncology Group. Semin Nucl Med 2002;32:141.
20. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med Mol Imaging 1999;26:1439.
21. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188.
22. Cardoso A, el Ghamrawy C, Gautron JP, et al. Somatostatin increases mitogen-induced IL-2 secretion and proliferation of human Jurkat T-cells via sst3 receptor isotype. J Cell Biochem 1998;68:62.
23. Lichtenauer-Kaligis EG, Dalm VA, Oomen SP, et al. Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. Eur J Endocrinol 2004;150:565. Erratum in: Eur J Endocrinol 2005;152:325.
24. Tsutsumi A, Takano H, Ichikawa K, et al. Expression of somatostatin receptor subtype 2mRNA in human lymphoid cells. Cell Immunol 1997;181:44.
25. Reubi JC, Waser B, Horisberger U, et al. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 1993;82: 2143.
26. Ferone D, Hofland LJ, Colao A, et al. Neuroendocrine aspects of immunolymphoproliferative diseases [review]. Ann Oncol 2001;12(Suppl 2):S125.
27. Agazzi A, Rocca P, Laszlo D, et al. Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders? Eur J Haematol 2005;74:450.
28. Ferone D, van Hagen MP, Kwekkeboom DJ, et al. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 2000;85:1719.
29. Dalm VA, Hofland LJ, Mooy CM, et al. Somatostatin receptors in malignant lymphomas: Targets for radiotherapy? J Nucl Med 2004;45:8.
30. Keller G, Engel JB, Schally AV, et al. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue, AN-238. Int J Cancer 2005; 114:831.
31. Witzig TE, Letendre L, Gerstner J, et al. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: Results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol 1995;13:2012.